Plain-English translation of NCT03240328 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether CAR-T cell therapy—a treatment that uses your own immune cells that have been genetically engineered in a lab—can help your body eliminate hidden HIV that remains even when standard HIV medications keep your virus undetectable. The trial will look at whether this medication is safe and whether it can reduce the viral reservoir (the hidden HIV that persists in your body).
Even though modern HIV medications work very well at stopping the virus from multiplying, the virus can hide in your body in a dormant state. This trial exists to see if this new treatment can help your immune system find and destroy those hidden viral cells, potentially moving closer to a cure for HIV.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive one or two infusions of the engineered after your HIV has been well controlled on your regular HIV medications. After receiving the treatment, you would have close medical follow-up to watch for any side effects and to see how your body responds. If your virus stays undetectable, your doctor may consider pausing your regular HIV medications while closely monitoring you—but if your virus starts to rebound, you would restart your HIV medications right away.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Guangzhou 8th People's Hospital
Collaborators
Sun Yat-sen University
Enrollment target
~40 participants
Started
October 2017
Primary completion
December 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in September 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Li Linghua, Doctor
Guangzhou 8th People's Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.